Literature DB >> 20670044

Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.

Antonio Gatti1, Elisabetta Sabato, Anna Rita Di Paolo, Massimo Mammucari, Alessandro Fabrizio Sabato.   

Abstract

The combination of two analgesic agents offers several advantages in the treatment of chronic pain. Paracetamol (acetaminophen) has central analgesic activity without a nonsteroidal anti-inflammatory drug (NSAID)-like or opioid-like effect. Oxycodone is a semisynthetic opioid agonist. The oral fixed-dose combination of oxycodone and paracetamol immediate-release formulation has a synergistic mechanism of action that is useful for moderate-to-severe pain and for nonresponders to NSAIDs or paracetamol alone. This fixed-dose combination offers several advantages: lower individual drug doses can be used because of their synergistic mechanisms of action, its opioid-sparing effect and it has a good efficacy and tolerability profile. Efficacy and safety of this fixed-dose combination were assessed in a wide range of clinical settings: in patients with osteoarthritis or chronic musculoskeletal pain, including when complicated by a neuropathic component; for chronic pain in elderly patients; cancer-related pain; postoperative pain; and for neuropathic pain, in the latter case usually given in combination with an NSAID or other drugs. The large variety of indications for which this fixed-dose combination may be useful can be attributed to the pharmacological synergy between oxycodone and paracetamol and because lower individual drug dosages can be used, suggesting that this should be a first-line agent for the treatment of chronic moderate-to-severe pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670044     DOI: 10.2165/1158414-S0-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  44 in total

Review 1.  New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases.

Authors:  David M Aronoff; John A Oates; Olivier Boutaud
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

2.  Early management of persistent non-specific low back pain: summary of NICE guidance.

Authors:  Pauline Savigny; Paul Watson; Martin Underwood
Journal:  BMJ       Date:  2009-06-04

3.  Central analgesic effect of acetaminophen but not of aspirin.

Authors:  P Piletta; H C Porchet; P Dayer
Journal:  Clin Pharmacol Ther       Date:  1991-04       Impact factor: 6.875

4.  Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism.

Authors:  Gisèle Pickering; Marie-Anne Loriot; Frédéric Libert; Alain Eschalier; Philippe Beaune; Claude Dubray
Journal:  Clin Pharmacol Ther       Date:  2006-04       Impact factor: 6.875

5.  Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato; Annalisa Carucci; Laura Bertini; Massimo Mammucari; Roberto Occhioni
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

6.  Combination analgesics.

Authors:  W T Beaver
Journal:  Am J Med       Date:  1984-09-10       Impact factor: 4.965

Review 7.  [Antinociceptive mechanism of action of paracetamol].

Authors:  Jérôme Bonnefont; Jean-Philippe Courade; Abdelkrim Alloui; Alain Eschalier
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain.

Authors:  Arnold R Gammaitoni; Bradley S Galer; Scott Bulloch; Peter Lacouture; Frank Caruso; Tina Ma; Thomas Schlagheck
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

9.  Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.

Authors:  C P Watson; N Babul
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 10.  Tolerability of paracetamol.

Authors:  Garry G Graham; Kieran F Scott; Richard O Day
Journal:  Drug Saf       Date:  2005       Impact factor: 5.228

View more
  8 in total

Review 1.  Preclinical pharmacology and opioid combinations.

Authors:  Gavril W Pasternak
Journal:  Pain Med       Date:  2012-03       Impact factor: 3.750

2.  Oral oxycodone plus intravenous acetaminophen versus intravenous morphine sulfate in acute bone fracture pain control: a double-blind placebo-controlled randomized clinical trial.

Authors:  Mohammad Amin Zare; Alireza Hassan Ghalyaie; Marzieh Fathi; Davood Farsi; Saeed Abbasi; Peyman Hafezimoghadam
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-12-20

3.  The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.

Authors:  Joseph V Pergolizzi; Robert Taylor; Robert B Raffa
Journal:  Adv Ther       Date:  2015-05-31       Impact factor: 3.845

4.  Consumer concerns about paracetamol: a retrospective analysis of a medicines call centre.

Authors:  Stephanie M Lau; Treasure M McGuire; Mieke L van Driel
Journal:  BMJ Open       Date:  2016-06-08       Impact factor: 2.692

5.  Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain.

Authors:  Stefano De Santis; Maria Domenica Simone; Sebastiano Mercadante; Rocco Domenico Mediati; Renato Vellucci; Paolo Marchetti; Giuseppe Tonini; Arturo Cuomo; Augusto Caraceni; Silvia Natoli; Grazia Armento; Livio Blasi; Massimo Mammucari
Journal:  Cancer Manag Res       Date:  2021-02-19       Impact factor: 3.989

6.  Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone.

Authors:  Scott G Weiner; Michelle A Hendricks; Sanae El Ibrahimi; Grant A Ritter; Sara E Hallvik; Christi Hildebran; Roger D Weiss; Edward W Boyer; Diana P Flores; Lewis S Nelson; Peter W Kreiner; Michael A Fischer
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.240

7.  Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.

Authors:  Krishna Devarakonda; Terri Morton; Rachel Margulis; Michael Giuliani; Thomas Barrett
Journal:  Drug Des Devel Ther       Date:  2014-08-19       Impact factor: 4.162

Review 8.  Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?

Authors:  Domenico Spina
Journal:  Eur Clin Respir J       Date:  2015-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.